{"ticker": {"uuid": "63c45c76-5c77-45d7-9d65-6fa5215966d2", "symbol": "IFRX", "name": "InflaRx N.V.", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "IFRX - InflaRx NV Revenue Breakdown", "summary": "This article provides a detailed financial breakdown for InflaRx NV (IFRX), including its market capitalization, enterprise value, various ratios like P/B and Quick Ratio, and performance metrics such as EPS growth rates and sales figures. It also lists insider and institutional ", "url": "https://finviz.com/stock?t=IFRX&ty=rv&p=d", "source_name": "Finviz", "published_at": "2026-07-05T15:40:36", "published_display": "05 Jul 2026 15:40", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of InflaRx N.V. \u2013 NASDAQ:IFRX", "summary": "This article provides \"Price to earnings forward\" data for InflaRx N.V. (NASDAQ: IFRX), a biotechnology company. It presents a specific financial metric for the company, indicating its valuation based on future earnings, but the value itself is redacted. The page structure sugges", "url": "https://www.tradingview.com/symbols/NASDAQ-IFRX/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T03:39:20", "published_display": "05 Jul 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of InflaRx N.V. \u2013 MUN:IF0", "summary": "This article provides financial information for InflaRx N.V. (IF0) on the Munich Stock Exchange, specifically focusing on its forward price-to-earnings ratio. The content is part of a larger financial data platform, TradingView, which offers various market tools and information.", "url": "https://www.tradingview.com/symbols/MUN-IF0/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T02:09:27", "published_display": "05 Jul 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "InflaRx regains Nasdaq compliance after shares trade above $1", "summary": "InflaRx has successfully regained compliance with Nasdaq's minimum bid price requirement as its shares have traded above $1 for ten consecutive business days. This marks a positive development for the biotech company, which had previously received a deficiency notice from Nasdaq ", "url": "https://www.msn.com/tr-tr/finans/onecikanhissesenetleri/inflarx-regains-nasdaq-compliance-after-shares-trade-above-1/ar-AA21Uut4", "source_name": "MSN", "published_at": "2026-07-02T20:13:48", "published_display": "02 Jul 2026 20:13", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of InflaRx N.V. \u2013 NASDAQ:IFRX", "summary": "This article provides financial data for InflaRx N.V. (NASDAQ: IFRX), specifically focusing on its Price to Book Forward metric. The content highlights the stock's market status, financial overview, and general information available on the TradingView platform.", "url": "https://www.tradingview.com/symbols/NASDAQ-IFRX/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T22:40:28", "published_display": "01 Jul 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "InflaRx (IFRX) rethinks European AAV path after EMA Tavneos setback", "summary": "InflaRx (IFRX) is reassessing its strategy for ANCA-associated vasculitis (AAV) in Europe following the EMA's Committee for Medicinal Products for Human Use recommendation to revoke Tavneos' marketing authorization. The company plans to engage with the EMA regarding its C5a-targe", "url": "https://www.stocktitan.net/sec-filings/IFRX/6-k-infla-rx-n-v-current-report-foreign-issuer-e244efb66881.html", "source_name": "Stock Titan", "published_at": "2026-06-30T20:11:04", "published_display": "30 Jun 2026 20:11", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "InflaRx to Engage EMA on Vilobelimab and Izicopan Development Path in AAV", "summary": "InflaRx N.V. intends to engage with the European Medicines Agency (EMA) to discuss the regulatory approval pathways for its therapies, vilobelimab and izicopan, for ANCA-associated vasculitis (AAV). This decision comes after the EMA's recommendation to revoke the marketing author", "url": "https://www.quiverquant.com/news/InflaRx+to+Engage+EMA+on+Vilobelimab+and+Izicopan+Development+Path+in+AAV", "source_name": "Quiver Quantitative", "published_at": "2026-06-30T11:41:00", "published_display": "30 Jun 2026 11:41", "sentiment": "positive", "sentiment_pct": 67, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EMA move on Tavneos pushes InflaRx to widen AAV plan in Europe", "summary": "InflaRx is broadening its ANCA-associated vasculitis (AAV) strategy in Europe by evaluating regulatory paths for its drugs vilobelimab and izicopan, following the EMA\u2019s recommendation to revoke Tavneos\u2019 authorization. The company plans discussions with the EMA regarding both comp", "url": "https://www.stocktitan.net/news/IFRX/infla-rx-assessing-feasibility-of-broadened-strategy-for-anca-qtj894w1zana.html", "source_name": "Stock Titan", "published_at": "2026-06-30T11:12:27", "published_display": "30 Jun 2026 11:12", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "InflaRx Assessing Feasibility of Broadened Strategy for ANCA\u2011Associated Vasculitis in Europe Following EMA Recommendation on Tavneos", "summary": "InflaRx is evaluating a broader strategy for ANCA-associated vasculitis (AAV) in Europe following the EMA's recommendation to revoke marketing authorization for Tavneos. The company plans to engage with the EMA regarding its anti-C5a antibody vilobelimab and oral C5aR inhibitor i", "url": "https://www.globenewswire.com/news-release/2026/06/30/3319558/0/en/inflarx-assessing-feasibility-of-broadened-strategy-for-anca-associated-vasculitis-in-europe-following-ema-recommendation-on-tavneos.html", "source_name": "GlobeNewswire", "published_at": "2026-06-30T11:12:27", "published_display": "30 Jun 2026 11:12", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of InflaRx N.V. \u2013 NASDAQ:IFRX", "summary": "This article provides financial data specifically focusing on the \"Price to sales forward\" for InflaRx N.V. (NASDAQ: IFRX). It likely presents a table or chart displaying the value, change, and percentage change of this metric over a specific period. The content is primarily a da", "url": "https://www.tradingview.com/symbols/NASDAQ-IFRX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T14:12:56", "published_display": "29 Jun 2026 14:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of InflaRx N.V. \u2013 GETTEX:IF0", "summary": "This article provides access to the \"Price to book forward\" metric for InflaRx N.V. traded on GETTEX with the symbol IF0. It is a technical financial data point made by humans, likely for investors and analysts to evaluate the company. The content itself doesn't present the data ", "url": "https://www.tradingview.com/symbols/GETTEX-IF0/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T13:12:28", "published_display": "29 Jun 2026 13:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of InflaRx N.V. \u2013 GETTEX:IF0", "summary": "This article displays the \"Price to sales forward\" financial metric for InflaRx N.V. (GETTEX:IF0) on TradingView. It shows the period, value, and change information for this specific financial data point. The article is a snapshot from the financial analysis platform.", "url": "https://www.tradingview.com/symbols/GETTEX-IF0/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T01:41:40", "published_display": "29 Jun 2026 01:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of InflaRx N.V. \u2013 NASDAQ:IFRX", "summary": "The article focuses on the enterprise value to revenue forward metric for InflaRx N.V., traded on NASDAQ under the symbol IFRX. It appears to be a financial data snippet or a specific analytical view provided by TradingView, although no detailed financial figures are present in t", "url": "https://www.tradingview.com/symbols/NASDAQ-IFRX/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T20:39:41", "published_display": "28 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in InflaRx N.V. Stocks", "summary": "This article lists ETFs that hold InflaRx N.V. stocks, providing details such as market value, weight, issuer, and performance metrics. It highlights how these funds make stock investing more accessible and offer diversified opportunities with lower risk. The specific ETF mention", "url": "https://www.tradingview.com/symbols/DUS-IF0/etfs/", "source_name": "TradingView", "published_at": "2026-06-28T12:41:41", "published_display": "28 Jun 2026 12:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "InflaRx N.V. Actuals & Estimates (HAM:IF0)", "summary": "This article provides an overview of InflaRx N.V. (HAM:IF0) stock, including financial actuals and estimates, analyst forecasts, historical price data, and upcoming earnings dates. It also covers the company's revenue, net income, employee count, and information on how to trade i", "url": "https://www.tradingview.com/symbols/HAM-IF0/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T04:10:20", "published_display": "26 Jun 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "InflaRx NV (IFRX) price target decreased by 16.67% to 7.29", "summary": "This article reports that the price target for InflaRx NV (IFRX) has been reduced by 16.67%, bringing it down to $7.29. The headline serves as the sole piece of information available from the provided content.", "url": "https://www.msn.com/en-us/money/topstocks/inflarx-nv-ifrx-price-target-decreased-by-1667-to-729/ar-AA23av4v?ocid=BingNewsVerp&apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-06-23T15:10:05", "published_display": "23 Jun 2026 15:10", "sentiment": "negative", "sentiment_pct": 29, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "InflaRx NV (IFRX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for InflaRx NV (IFRX), highlighting its current earnings forecast score, average price target, and analyst ratings. Based on 8 analysts, the consensus is a \"Buy\" rating with an average target price of $8.00, suggesting a significant upsi", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ifrx/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T09:11:24", "published_display": "18 Jun 2026 09:11", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "InflaRx NV (IFRX) Institutional Confidence", "summary": "This article from TradingKey focuses on the institutional confidence score for InflaRx NV (IFRX), which currently stands at 3.00, unchanged from its previous score. The report details significant institutional shareholdings and recent changes in share percentages by various firms", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ifrx/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T09:09:12", "published_display": "18 Jun 2026 09:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "InflaRx NV (IFRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for InflaRx NV (IFRX), focusing on business segments and regional contributions. As of the May 5, 2025 update, key relevant financial data regarding specific regional and business segment revenues has not yet been disclosed by the company", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ifrx/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T06:47:32", "published_display": "18 Jun 2026 06:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "InflaRx NV (IFRX) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article provides an analysis of InflaRx NV's (IFRX) financial health, noting its current score of 6.64 and ranking within the Biotechnology & Medical Research industry. It identifies the company's financial status as weak despite high operating efficiency. The report indicat", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ifrx/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T05:40:35", "published_display": "18 Jun 2026 05:40", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "InflaRx NV (IFRX) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of InflaRx NV's (IFRX) dividend and stock split history. It notes that the company has distributed $0.00 in dividends over the past five years and lists no historical stock splits, indicating a lack of such events for IFRX within the recorded per", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ifrx/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T21:40:32", "published_display": "17 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "InflaRx NV (IFRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of InflaRx NV (IFRX), detailing its price momentum, support and resistance levels, and various technical indicators and moving averages. The stock currently has a price momentum score of 6.81, ranking 208th in its industry, and is tradin", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ifrx/technical", "source_name": "TradingKey", "published_at": "2026-06-17T20:10:57", "published_display": "17 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Do Analysts Say About InflaRx N.V. (IFRX)?", "summary": "Analysts are bullish on InflaRx N.V. (IFRX), with a consensus median price target of $8.95 and strong ratings, despite shares trading under $2. The positive sentiment follows upgrades from Raymond James and H.C. Wainwright, citing the izicopan program in ANCA-associated vasculiti", "url": "https://uk.finance.yahoo.com/news/analysts-inflarx-n-v-ifrx-182242349.html", "source_name": "Market source", "published_at": "2026-06-10T18:22:00", "published_display": "10 Jun 2026 18:22", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "InflaRx to develop izicopan for kidney disease treatment", "summary": "InflaRx N.V. (NASDAQ:IFRX) is advancing the development of izicopan, an oral C5a receptor inhibitor, for ANCA-associated vasculitis and other complement-mediated kidney diseases. The biopharmaceutical company plans Phase 2 studies and open-label studies for various indications, e", "url": "https://www.investing.com/news/company-news/inflarx-to-develop-izicopan-for-kidney-disease-treatment-93CH-4663239", "source_name": "Investing.com", "published_at": "2026-06-04T14:39:00", "published_display": "04 Jun 2026 14:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "InflaRx NV stock (NL0012661870): Nasdaq-listed biotech trades lower ahead of next earnings update", "summary": "InflaRx NV's Nasdaq-listed stock (IFRX) experienced a 5% dip to around USD 2.28 in early June 2026, ahead of its next quarterly earnings update. Despite an average twelve-month price target of USD 7.00 from analysts earlier in the year, the current trading price reflects signific", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/inflarx-nv-stock-nl0012661870-nasdaq-listed-biotech-trades-lower-ahead/69473477", "source_name": "Ad Hoc News", "published_at": "2026-06-03T01:01:54", "published_display": "03 Jun 2026 01:01", "sentiment": "negative", "sentiment_pct": 36, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here\u2019s Why InflaRx (IFRX) is Among the 10 Most Volatile Penny Stocks to Buy Now", "summary": "InflaRx N.V. (NASDAQ:IFRX) has received upgraded ratings and price targets from Raymond James and H.C. Wainwright, with analysts citing the company's izicopan program for ANCA-associated vasculitis (AAV) and its adjusted clinical focus. InflaRx plans to develop izicopan, an oral ", "url": "https://uk.finance.yahoo.com/news/why-inflarx-ifrx-among-10-105555825.html", "source_name": "Market source", "published_at": "2026-05-31T11:09:17", "published_display": "31 May 2026 11:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Farallon funds and managers report shared stakes in InflaRx (IFRX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOSWh5bFIxQzRJNk9ILVBETGJSUU9neFViUm9IOGFDNmdPYkNyYlJXUlR4WThxdnBkTGJZVVhQVUc0Vll4WEgwWkhXX2drYldCMGtheGF5T1I5NlhiSkRfdVd6RHBVLVRBNnNkbkcyQm1XSFZ2WXlDbExxMjN6LVhYQlh6UDlMVWVRWHpoYTkyQ3NRVTZYX0UtTlZVaE5ZLUNERjdxel9ZWURtY1I4T2pnYWxyTzdoNmtXazZn?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "InflaRx Investor Update: Izicopan Set to Take Center Stage in AAV and Renal Disease Pipeline", "summary": "", "url": "https://finance.yahoo.com/m/3f0b4154-87cb-30a5-8fc6-8896dc06a531/inflarx-investor-update%3A.html", "source_name": "MarketBeat", "published_at": "2026-05-08T15:53:13+00:00", "published_display": "08 May 2026 15:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6AFBVV95cUxOR05qbGdfREZRQVpmbi12RUMwUTdhQkZNbVdlWFhqb0tCTGZUMk5ZczZMV0hHR2JwZEFwQ1VScGtheFZYOHBXZFVkRHVhbVRNYUNTSXFJOFd6RzdCaDM3Rm15aHZqUVhGajh6U0tuSGxBMHRPN3NhLU55bVJDbmFUS0xTY09YVjE2emJLZ09RbFYwT1Y2VkhKZ1VIdGpBZi1rM2FON3hnR0QtZUpHQjhfTlc3SmNKSGo2QWRiTzFUMmE0ZmxGUGlZNkhtZkZ6dFh6S2gyZmZ2QnlhSThNQjFHX0xfRFRFRXZE?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "InflaRx attracts strong investor interest with US share offering turning to kidney", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxPSlFfVmNpYXB2SGt1S3FuQmhQSmNfRTFxM2lnRE9pa09fRVByREdGS3NOVlFoNUh2RnN5bHV2VUZOREgtNHRWd3J4ZVZRaWlHX2dTakQ4emduN1VXNVdURkREZ3FKdGdfV1hJVUFXSGtIN2QxNzBndm5laVNJRGhwM0wzeVNMU1UyZjV3dEh6WDdCUnVTZXVibmszR1JnazZnTjkyc2tNeWhhRFRhZmRHREJDUmFaczE4MnNwdUJFUldBTEg2MFQ1RGJR?oc=5", "source_name": "European Biotechnology Magazine", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "InflaRx (NASDAQ: IFRX) raises $150M in underwritten share sale", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNMFJnZWhtRUFfX0ltSVp5a0lQNVBfNFoyR2NBOVlnak9NWEcwMVBVeVZ1eFlfU2F0NlpMZXU4cDRPRXlKVlZpdGctMDlyRVBrSVZ3TGJiZ2NLUlhfZUZnM244bXp1UHdac21rV1RSQXctTGFzMmVucWU5RGpPWG5rckpfUGVsVUpqRDFYZ3UxdmNqRm9WVXZabWpHdjZyQ2FRZURmNXE3N3pnZjMx?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "InflaRx N.V. (IFRX) Regains Compliance With Nasdaq", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxPVmotS0VvSXBCM1RzTEVRTVRQRjR2TG1NbWRfQ055VUxUSGlNX0szcXpGRzJ0RzhDRExvdVhYd2ktV1l6MUFZTmZGcGJzS2FOUHE5SWVGdjVIdXZ6cmZJYkRmc1prN1NkVFZjbl80Zjh5akVoWl94Vm52VGRNZ08yR3h3NGFkaFNLRUhwY1ZZLV9UQnc?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/inflarx-announces-pricing-150-million-123000602.html", "source_name": "GlobeNewswire", "published_at": "2026-05-06T12:30:00+00:00", "published_display": "06 May 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/inflarx-announces-advancement-izicopan-anca-122500050.html", "source_name": "GlobeNewswire", "published_at": "2026-05-06T12:25:00+00:00", "published_display": "06 May 2026 12:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Funded through 2029, InflaRx expands izicopan into kidney diseases", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQWlh4NFZvWmp5UW1ZLW9ZVzRtMmNkVUFsbEhMRkYwTngzdldrMnBHZnpDb2JtM0h3VThJTkptZXFIRTc3a2FYVVJQaUFpM3o3LW5OVExpMzlhaXd5RjFEdFJFZ2JwSENEcnRXYi1qcy1sNUI5dFdKMWdkTHZ2ZjRQZTlWQlhOVjNzeVNISFlCUmpwLTg1djJiQzdpdFNVc2FVS0RhTUlzeEJHQkcwc2pQemtNUDk2WFE?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "InflaRx prices $150M stock sale to fund pipeline and working capital", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOU3ROYS13LUVtYTVVTERXcE8tWDh4d3RsZGg1VmJQOG9VcHRGUTNoMzlDaWV3bDVYcjlmb3pFLUlYNjg1WlBwQy1GVHdXdlp6clZ5aG1vX2k0ejdnRkR6ejI0Uk5oaDVrZWRGOHdzRUxMVzQtVEtQVjVENGxTMlAtZkdVTk1GaTBpb0IyUzh5WDRsNVNhZDJpTUpHMG01Q1BKMFlrdEZfdklHaWdobEE4MkVxU2lJZ0xzWTFfWWJ3?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/inflarx-reports-favorable-reactive-metabolite-113000781.html", "source_name": "GlobeNewswire", "published_at": "2026-05-04T11:30:00+00:00", "published_display": "04 May 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "No conference call: InflaRx to post Q1 2026 results on May 7", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxQdTFXcy1lYTJIWWZFOWtDbWRteGtEM3NSZmNfbmd6MDFjWGJDVUJWdm5pV3B5RWNtREM2ZVhwRHhjQ1k5U3VmbjNuSUFsN0Q0OS10YUZKSGxJZEh5cU9BZmFjR0gzc1JNakcxRm4xbEN3Y2s2T3hCSXV0Q0pqMVlYdzJUV01MS2U2cFNuaDVqZ2NMVkpybzhrLVVnWXlDRTNOWlVLR1owTkpFekhFTmc?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "InflaRx (Nasdaq: IFRX) back in line with Nasdaq minimum bid price rule", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPaFRSVWxmd0ZxSGV5b0V1UGNzcmo4cGRRek1qSGl4WjJaMy01Q1M3b0YwMkZFS1RNNWk0dmhMblZZcDlyeTJSRXdLNGt4S1ZVOG9sTkJuc21YN3VfaldsQVpQYlBxRThxVnpNQWxnZl9vZFJDc2pDc05HVXpLUHo2U2JzSVJENEd1M0JuNl9wVC1qdlhNdXZuM0R6eERkV2h0LUJSTWlsQ01CZW9H?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nasdaq closes InflaRx listing issue after stock holds above $1", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNR3AyaU8tNFgtTWYzaEsyYjdXSE94QzBzWTQ4aGlkcVF6WnhTeXIzNXFhZWh4bkRqeU5RaEVNRHJteXlaeGxqVFpnLWd1OS0zb1RkNzRqaDhPNUdhal9VZTQ4WUl3V2tsUHVVNk91RTFQUlYxcmtndndNWkxXOUJpeVgtZVl0ZEVOeFpTSEFmcU5vdmlnMHdtbWdEeUFiM2xvNFE5SlVhOFJ0b01BY2Y3Qk9R?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Here's Why InflaRx (NASDAQ:IFRX) Must Use Its Cash Wisely", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxOYmJUdXh4NndwUTBDUTkxOW5yQVVVWWtJVHFNcEd0MzItX2p3R3VHWS1HT2hIa2lkX3k1R2d0UXBycTNIdkkzVVV4OTVxaUw1OUVUT29BZnM2MHZScnJlYl9FNTVpNFBMdy0wbURjTU5aRFpjVjJBOG9jMjBFX0l4RA?oc=5", "source_name": "Market source", "published_at": "2026-02-02T08:00:00+00:00", "published_display": "02 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inflarx (IFRX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE9wSzItdHg3aGFLdkFOUFR4azYtTmtqSXNsekNudVpqaDI3SkEtUTJqRzYzMldhNmhHb2ttT3pzdHY0NWp6N1B5ZEVTTlRDQkJQNk5v?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-24T23:56:28+00:00", "published_display": "24 Apr 2025 23:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "InflaRx (IFRX) Stock Price, News & Analysis $IFRX", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE40ZWNDWG1zX3BqY0VXMmxHYkx4eXBINTBxQUh3Skh2NGpsR1RmUDJncWo1eWhNcVhPZDhZcHVwYUZ6ZjFtc2dtTjAyN2Q1dlh1U3V2eHloVFhHUQ?oc=5", "source_name": "MarketBeat", "published_at": "2017-11-29T04:53:39+00:00", "published_display": "29 Nov 2017 04:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IFRX Stock Price and Chart \u2014 NASDAQ:IFRX", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE05a3F1WFZVdm0taFduZEpJSVJSQ3B4TEZZWHVEMUdCaW0xZUpMOEFVYnZNNXhhREVQMlh4U252NXo2NzF0Z3VkTWhVV0JUOVRqWi0yWEVsMS1RZlFx?oc=5", "source_name": "TradingView", "published_at": "2017-11-11T03:02:56+00:00", "published_display": "11 Nov 2017 03:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "IFRX - InflaRx NV Revenue Breakdown", "summary": "This article provides a detailed financial breakdown for InflaRx NV (IFRX), including its market capitalization, enterprise value, various ratios like P/B and Quick Ratio, and performance metrics such as EPS growth rates and sales figures. It also lists insider and institutional ", "url": "https://finviz.com/stock?t=IFRX&ty=rv&p=d", "source_name": "Finviz", "published_at": "2026-07-05T15:40:36", "published_display": "05 Jul 2026 15:40", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of InflaRx N.V. \u2013 NASDAQ:IFRX", "summary": "This article provides \"Price to earnings forward\" data for InflaRx N.V. (NASDAQ: IFRX), a biotechnology company. It presents a specific financial metric for the company, indicating its valuation based on future earnings, but the value itself is redacted. The page structure sugges", "url": "https://www.tradingview.com/symbols/NASDAQ-IFRX/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T03:39:20", "published_display": "05 Jul 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of InflaRx N.V. \u2013 MUN:IF0", "summary": "This article provides financial information for InflaRx N.V. (IF0) on the Munich Stock Exchange, specifically focusing on its forward price-to-earnings ratio. The content is part of a larger financial data platform, TradingView, which offers various market tools and information.", "url": "https://www.tradingview.com/symbols/MUN-IF0/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T02:09:27", "published_display": "05 Jul 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "InflaRx regains Nasdaq compliance after shares trade above $1", "summary": "InflaRx has successfully regained compliance with Nasdaq's minimum bid price requirement as its shares have traded above $1 for ten consecutive business days. This marks a positive development for the biotech company, which had previously received a deficiency notice from Nasdaq ", "url": "https://www.msn.com/tr-tr/finans/onecikanhissesenetleri/inflarx-regains-nasdaq-compliance-after-shares-trade-above-1/ar-AA21Uut4", "source_name": "MSN", "published_at": "2026-07-02T20:13:48", "published_display": "02 Jul 2026 20:13", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of InflaRx N.V. \u2013 NASDAQ:IFRX", "summary": "This article provides financial data for InflaRx N.V. (NASDAQ: IFRX), specifically focusing on its Price to Book Forward metric. The content highlights the stock's market status, financial overview, and general information available on the TradingView platform.", "url": "https://www.tradingview.com/symbols/NASDAQ-IFRX/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T22:40:28", "published_display": "01 Jul 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "InflaRx (IFRX) rethinks European AAV path after EMA Tavneos setback", "summary": "InflaRx (IFRX) is reassessing its strategy for ANCA-associated vasculitis (AAV) in Europe following the EMA's Committee for Medicinal Products for Human Use recommendation to revoke Tavneos' marketing authorization. The company plans to engage with the EMA regarding its C5a-targe", "url": "https://www.stocktitan.net/sec-filings/IFRX/6-k-infla-rx-n-v-current-report-foreign-issuer-e244efb66881.html", "source_name": "Stock Titan", "published_at": "2026-06-30T20:11:04", "published_display": "30 Jun 2026 20:11", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "InflaRx to Engage EMA on Vilobelimab and Izicopan Development Path in AAV", "summary": "InflaRx N.V. intends to engage with the European Medicines Agency (EMA) to discuss the regulatory approval pathways for its therapies, vilobelimab and izicopan, for ANCA-associated vasculitis (AAV). This decision comes after the EMA's recommendation to revoke the marketing author", "url": "https://www.quiverquant.com/news/InflaRx+to+Engage+EMA+on+Vilobelimab+and+Izicopan+Development+Path+in+AAV", "source_name": "Quiver Quantitative", "published_at": "2026-06-30T11:41:00", "published_display": "30 Jun 2026 11:41", "sentiment": "positive", "sentiment_pct": 67, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EMA move on Tavneos pushes InflaRx to widen AAV plan in Europe", "summary": "InflaRx is broadening its ANCA-associated vasculitis (AAV) strategy in Europe by evaluating regulatory paths for its drugs vilobelimab and izicopan, following the EMA\u2019s recommendation to revoke Tavneos\u2019 authorization. The company plans discussions with the EMA regarding both comp", "url": "https://www.stocktitan.net/news/IFRX/infla-rx-assessing-feasibility-of-broadened-strategy-for-anca-qtj894w1zana.html", "source_name": "Stock Titan", "published_at": "2026-06-30T11:12:27", "published_display": "30 Jun 2026 11:12", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "InflaRx Assessing Feasibility of Broadened Strategy for ANCA\u2011Associated Vasculitis in Europe Following EMA Recommendation on Tavneos", "summary": "InflaRx is evaluating a broader strategy for ANCA-associated vasculitis (AAV) in Europe following the EMA's recommendation to revoke marketing authorization for Tavneos. The company plans to engage with the EMA regarding its anti-C5a antibody vilobelimab and oral C5aR inhibitor i", "url": "https://www.globenewswire.com/news-release/2026/06/30/3319558/0/en/inflarx-assessing-feasibility-of-broadened-strategy-for-anca-associated-vasculitis-in-europe-following-ema-recommendation-on-tavneos.html", "source_name": "GlobeNewswire", "published_at": "2026-06-30T11:12:27", "published_display": "30 Jun 2026 11:12", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of InflaRx N.V. \u2013 NASDAQ:IFRX", "summary": "This article provides financial data specifically focusing on the \"Price to sales forward\" for InflaRx N.V. (NASDAQ: IFRX). It likely presents a table or chart displaying the value, change, and percentage change of this metric over a specific period. The content is primarily a da", "url": "https://www.tradingview.com/symbols/NASDAQ-IFRX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T14:12:56", "published_display": "29 Jun 2026 14:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of InflaRx N.V. \u2013 GETTEX:IF0", "summary": "This article provides access to the \"Price to book forward\" metric for InflaRx N.V. traded on GETTEX with the symbol IF0. It is a technical financial data point made by humans, likely for investors and analysts to evaluate the company. The content itself doesn't present the data ", "url": "https://www.tradingview.com/symbols/GETTEX-IF0/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T13:12:28", "published_display": "29 Jun 2026 13:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of InflaRx N.V. \u2013 GETTEX:IF0", "summary": "This article displays the \"Price to sales forward\" financial metric for InflaRx N.V. (GETTEX:IF0) on TradingView. It shows the period, value, and change information for this specific financial data point. The article is a snapshot from the financial analysis platform.", "url": "https://www.tradingview.com/symbols/GETTEX-IF0/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T01:41:40", "published_display": "29 Jun 2026 01:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of InflaRx N.V. \u2013 NASDAQ:IFRX", "summary": "The article focuses on the enterprise value to revenue forward metric for InflaRx N.V., traded on NASDAQ under the symbol IFRX. It appears to be a financial data snippet or a specific analytical view provided by TradingView, although no detailed financial figures are present in t", "url": "https://www.tradingview.com/symbols/NASDAQ-IFRX/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T20:39:41", "published_display": "28 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in InflaRx N.V. Stocks", "summary": "This article lists ETFs that hold InflaRx N.V. stocks, providing details such as market value, weight, issuer, and performance metrics. It highlights how these funds make stock investing more accessible and offer diversified opportunities with lower risk. The specific ETF mention", "url": "https://www.tradingview.com/symbols/DUS-IF0/etfs/", "source_name": "TradingView", "published_at": "2026-06-28T12:41:41", "published_display": "28 Jun 2026 12:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "InflaRx N.V. Actuals & Estimates (HAM:IF0)", "summary": "This article provides an overview of InflaRx N.V. (HAM:IF0) stock, including financial actuals and estimates, analyst forecasts, historical price data, and upcoming earnings dates. It also covers the company's revenue, net income, employee count, and information on how to trade i", "url": "https://www.tradingview.com/symbols/HAM-IF0/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T04:10:20", "published_display": "26 Jun 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "InflaRx NV (IFRX) price target decreased by 16.67% to 7.29", "summary": "This article reports that the price target for InflaRx NV (IFRX) has been reduced by 16.67%, bringing it down to $7.29. The headline serves as the sole piece of information available from the provided content.", "url": "https://www.msn.com/en-us/money/topstocks/inflarx-nv-ifrx-price-target-decreased-by-1667-to-729/ar-AA23av4v?ocid=BingNewsVerp&apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-06-23T15:10:05", "published_display": "23 Jun 2026 15:10", "sentiment": "negative", "sentiment_pct": 29, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "InflaRx NV (IFRX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for InflaRx NV (IFRX), highlighting its current earnings forecast score, average price target, and analyst ratings. Based on 8 analysts, the consensus is a \"Buy\" rating with an average target price of $8.00, suggesting a significant upsi", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ifrx/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T09:11:24", "published_display": "18 Jun 2026 09:11", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "InflaRx NV (IFRX) Institutional Confidence", "summary": "This article from TradingKey focuses on the institutional confidence score for InflaRx NV (IFRX), which currently stands at 3.00, unchanged from its previous score. The report details significant institutional shareholdings and recent changes in share percentages by various firms", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ifrx/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T09:09:12", "published_display": "18 Jun 2026 09:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "InflaRx NV (IFRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for InflaRx NV (IFRX), focusing on business segments and regional contributions. As of the May 5, 2025 update, key relevant financial data regarding specific regional and business segment revenues has not yet been disclosed by the company", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ifrx/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T06:47:32", "published_display": "18 Jun 2026 06:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "InflaRx NV (IFRX) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article provides an analysis of InflaRx NV's (IFRX) financial health, noting its current score of 6.64 and ranking within the Biotechnology & Medical Research industry. It identifies the company's financial status as weak despite high operating efficiency. The report indicat", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ifrx/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T05:40:35", "published_display": "18 Jun 2026 05:40", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "InflaRx NV (IFRX) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of InflaRx NV's (IFRX) dividend and stock split history. It notes that the company has distributed $0.00 in dividends over the past five years and lists no historical stock splits, indicating a lack of such events for IFRX within the recorded per", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ifrx/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T21:40:32", "published_display": "17 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "InflaRx NV (IFRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of InflaRx NV (IFRX), detailing its price momentum, support and resistance levels, and various technical indicators and moving averages. The stock currently has a price momentum score of 6.81, ranking 208th in its industry, and is tradin", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ifrx/technical", "source_name": "TradingKey", "published_at": "2026-06-17T20:10:57", "published_display": "17 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Do Analysts Say About InflaRx N.V. (IFRX)?", "summary": "Analysts are bullish on InflaRx N.V. (IFRX), with a consensus median price target of $8.95 and strong ratings, despite shares trading under $2. The positive sentiment follows upgrades from Raymond James and H.C. Wainwright, citing the izicopan program in ANCA-associated vasculiti", "url": "https://uk.finance.yahoo.com/news/analysts-inflarx-n-v-ifrx-182242349.html", "source_name": "Market source", "published_at": "2026-06-10T18:22:00", "published_display": "10 Jun 2026 18:22", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "InflaRx to develop izicopan for kidney disease treatment", "summary": "InflaRx N.V. (NASDAQ:IFRX) is advancing the development of izicopan, an oral C5a receptor inhibitor, for ANCA-associated vasculitis and other complement-mediated kidney diseases. The biopharmaceutical company plans Phase 2 studies and open-label studies for various indications, e", "url": "https://www.investing.com/news/company-news/inflarx-to-develop-izicopan-for-kidney-disease-treatment-93CH-4663239", "source_name": "Investing.com", "published_at": "2026-06-04T14:39:00", "published_display": "04 Jun 2026 14:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "InflaRx NV stock (NL0012661870): Nasdaq-listed biotech trades lower ahead of next earnings update", "summary": "InflaRx NV's Nasdaq-listed stock (IFRX) experienced a 5% dip to around USD 2.28 in early June 2026, ahead of its next quarterly earnings update. Despite an average twelve-month price target of USD 7.00 from analysts earlier in the year, the current trading price reflects signific", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/inflarx-nv-stock-nl0012661870-nasdaq-listed-biotech-trades-lower-ahead/69473477", "source_name": "Ad Hoc News", "published_at": "2026-06-03T01:01:54", "published_display": "03 Jun 2026 01:01", "sentiment": "negative", "sentiment_pct": 36, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here\u2019s Why InflaRx (IFRX) is Among the 10 Most Volatile Penny Stocks to Buy Now", "summary": "InflaRx N.V. (NASDAQ:IFRX) has received upgraded ratings and price targets from Raymond James and H.C. Wainwright, with analysts citing the company's izicopan program for ANCA-associated vasculitis (AAV) and its adjusted clinical focus. InflaRx plans to develop izicopan, an oral ", "url": "https://uk.finance.yahoo.com/news/why-inflarx-ifrx-among-10-105555825.html", "source_name": "Market source", "published_at": "2026-05-31T11:09:17", "published_display": "31 May 2026 11:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Farallon funds and managers report shared stakes in InflaRx (IFRX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOSWh5bFIxQzRJNk9ILVBETGJSUU9neFViUm9IOGFDNmdPYkNyYlJXUlR4WThxdnBkTGJZVVhQVUc0Vll4WEgwWkhXX2drYldCMGtheGF5T1I5NlhiSkRfdVd6RHBVLVRBNnNkbkcyQm1XSFZ2WXlDbExxMjN6LVhYQlh6UDlMVWVRWHpoYTkyQ3NRVTZYX0UtTlZVaE5ZLUNERjdxel9ZWURtY1I4T2pnYWxyTzdoNmtXazZn?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "InflaRx Investor Update: Izicopan Set to Take Center Stage in AAV and Renal Disease Pipeline", "summary": "", "url": "https://finance.yahoo.com/m/3f0b4154-87cb-30a5-8fc6-8896dc06a531/inflarx-investor-update%3A.html", "source_name": "MarketBeat", "published_at": "2026-05-08T15:53:13+00:00", "published_display": "08 May 2026 15:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6AFBVV95cUxOR05qbGdfREZRQVpmbi12RUMwUTdhQkZNbVdlWFhqb0tCTGZUMk5ZczZMV0hHR2JwZEFwQ1VScGtheFZYOHBXZFVkRHVhbVRNYUNTSXFJOFd6RzdCaDM3Rm15aHZqUVhGajh6U0tuSGxBMHRPN3NhLU55bVJDbmFUS0xTY09YVjE2emJLZ09RbFYwT1Y2VkhKZ1VIdGpBZi1rM2FON3hnR0QtZUpHQjhfTlc3SmNKSGo2QWRiTzFUMmE0ZmxGUGlZNkhtZkZ6dFh6S2gyZmZ2QnlhSThNQjFHX0xfRFRFRXZE?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "InflaRx attracts strong investor interest with US share offering turning to kidney", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxPSlFfVmNpYXB2SGt1S3FuQmhQSmNfRTFxM2lnRE9pa09fRVByREdGS3NOVlFoNUh2RnN5bHV2VUZOREgtNHRWd3J4ZVZRaWlHX2dTakQ4emduN1VXNVdURkREZ3FKdGdfV1hJVUFXSGtIN2QxNzBndm5laVNJRGhwM0wzeVNMU1UyZjV3dEh6WDdCUnVTZXVibmszR1JnazZnTjkyc2tNeWhhRFRhZmRHREJDUmFaczE4MnNwdUJFUldBTEg2MFQ1RGJR?oc=5", "source_name": "European Biotechnology Magazine", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "InflaRx (NASDAQ: IFRX) raises $150M in underwritten share sale", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNMFJnZWhtRUFfX0ltSVp5a0lQNVBfNFoyR2NBOVlnak9NWEcwMVBVeVZ1eFlfU2F0NlpMZXU4cDRPRXlKVlZpdGctMDlyRVBrSVZ3TGJiZ2NLUlhfZUZnM244bXp1UHdac21rV1RSQXctTGFzMmVucWU5RGpPWG5rckpfUGVsVUpqRDFYZ3UxdmNqRm9WVXZabWpHdjZyQ2FRZURmNXE3N3pnZjMx?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "InflaRx N.V. (IFRX) Regains Compliance With Nasdaq", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxPVmotS0VvSXBCM1RzTEVRTVRQRjR2TG1NbWRfQ055VUxUSGlNX0szcXpGRzJ0RzhDRExvdVhYd2ktV1l6MUFZTmZGcGJzS2FOUHE5SWVGdjVIdXZ6cmZJYkRmc1prN1NkVFZjbl80Zjh5akVoWl94Vm52VGRNZ08yR3h3NGFkaFNLRUhwY1ZZLV9UQnc?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/inflarx-announces-pricing-150-million-123000602.html", "source_name": "GlobeNewswire", "published_at": "2026-05-06T12:30:00+00:00", "published_display": "06 May 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/inflarx-announces-advancement-izicopan-anca-122500050.html", "source_name": "GlobeNewswire", "published_at": "2026-05-06T12:25:00+00:00", "published_display": "06 May 2026 12:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Funded through 2029, InflaRx expands izicopan into kidney diseases", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQWlh4NFZvWmp5UW1ZLW9ZVzRtMmNkVUFsbEhMRkYwTngzdldrMnBHZnpDb2JtM0h3VThJTkptZXFIRTc3a2FYVVJQaUFpM3o3LW5OVExpMzlhaXd5RjFEdFJFZ2JwSENEcnRXYi1qcy1sNUI5dFdKMWdkTHZ2ZjRQZTlWQlhOVjNzeVNISFlCUmpwLTg1djJiQzdpdFNVc2FVS0RhTUlzeEJHQkcwc2pQemtNUDk2WFE?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "InflaRx prices $150M stock sale to fund pipeline and working capital", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOU3ROYS13LUVtYTVVTERXcE8tWDh4d3RsZGg1VmJQOG9VcHRGUTNoMzlDaWV3bDVYcjlmb3pFLUlYNjg1WlBwQy1GVHdXdlp6clZ5aG1vX2k0ejdnRkR6ejI0Uk5oaDVrZWRGOHdzRUxMVzQtVEtQVjVENGxTMlAtZkdVTk1GaTBpb0IyUzh5WDRsNVNhZDJpTUpHMG01Q1BKMFlrdEZfdklHaWdobEE4MkVxU2lJZ0xzWTFfWWJ3?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/inflarx-reports-favorable-reactive-metabolite-113000781.html", "source_name": "GlobeNewswire", "published_at": "2026-05-04T11:30:00+00:00", "published_display": "04 May 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "No conference call: InflaRx to post Q1 2026 results on May 7", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxQdTFXcy1lYTJIWWZFOWtDbWRteGtEM3NSZmNfbmd6MDFjWGJDVUJWdm5pV3B5RWNtREM2ZVhwRHhjQ1k5U3VmbjNuSUFsN0Q0OS10YUZKSGxJZEh5cU9BZmFjR0gzc1JNakcxRm4xbEN3Y2s2T3hCSXV0Q0pqMVlYdzJUV01MS2U2cFNuaDVqZ2NMVkpybzhrLVVnWXlDRTNOWlVLR1owTkpFekhFTmc?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "InflaRx (Nasdaq: IFRX) back in line with Nasdaq minimum bid price rule", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPaFRSVWxmd0ZxSGV5b0V1UGNzcmo4cGRRek1qSGl4WjJaMy01Q1M3b0YwMkZFS1RNNWk0dmhMblZZcDlyeTJSRXdLNGt4S1ZVOG9sTkJuc21YN3VfaldsQVpQYlBxRThxVnpNQWxnZl9vZFJDc2pDc05HVXpLUHo2U2JzSVJENEd1M0JuNl9wVC1qdlhNdXZuM0R6eERkV2h0LUJSTWlsQ01CZW9H?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nasdaq closes InflaRx listing issue after stock holds above $1", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNR3AyaU8tNFgtTWYzaEsyYjdXSE94QzBzWTQ4aGlkcVF6WnhTeXIzNXFhZWh4bkRqeU5RaEVNRHJteXlaeGxqVFpnLWd1OS0zb1RkNzRqaDhPNUdhal9VZTQ4WUl3V2tsUHVVNk91RTFQUlYxcmtndndNWkxXOUJpeVgtZVl0ZEVOeFpTSEFmcU5vdmlnMHdtbWdEeUFiM2xvNFE5SlVhOFJ0b01BY2Y3Qk9R?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why InflaRx (NASDAQ:IFRX) Must Use Its Cash Wisely", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxOYmJUdXh4NndwUTBDUTkxOW5yQVVVWWtJVHFNcEd0MzItX2p3R3VHWS1HT2hIa2lkX3k1R2d0UXBycTNIdkkzVVV4OTVxaUw1OUVUT29BZnM2MHZScnJlYl9FNTVpNFBMdy0wbURjTU5aRFpjVjJBOG9jMjBFX0l4RA?oc=5", "source_name": "Market source", "published_at": "2026-02-02T08:00:00+00:00", "published_display": "02 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inflarx (IFRX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE9wSzItdHg3aGFLdkFOUFR4azYtTmtqSXNsekNudVpqaDI3SkEtUTJqRzYzMldhNmhHb2ttT3pzdHY0NWp6N1B5ZEVTTlRDQkJQNk5v?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-24T23:56:28+00:00", "published_display": "24 Apr 2025 23:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "InflaRx (IFRX) Stock Price, News & Analysis $IFRX", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE40ZWNDWG1zX3BqY0VXMmxHYkx4eXBINTBxQUh3Skh2NGpsR1RmUDJncWo1eWhNcVhPZDhZcHVwYUZ6ZjFtc2dtTjAyN2Q1dlh1U3V2eHloVFhHUQ?oc=5", "source_name": "MarketBeat", "published_at": "2017-11-29T04:53:39+00:00", "published_display": "29 Nov 2017 04:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IFRX Stock Price and Chart \u2014 NASDAQ:IFRX", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE05a3F1WFZVdm0taFduZEpJSVJSQ3B4TEZZWHVEMUdCaW0xZUpMOEFVYnZNNXhhREVQMlh4U252NXo2NzF0Z3VkTWhVV0JUOVRqWi0yWEVsMS1RZlFx?oc=5", "source_name": "TradingView", "published_at": "2017-11-11T03:02:56+00:00", "published_display": "11 Nov 2017 03:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 90, "total_relevant": 52, "sentiment_summary": {"positive": 13, "negative": 5, "neutral": 34, "score": 53, "total": 52, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 80, "events": [{"event": "general", "label": "Market update", "weight": 15.95, "count": 29}, {"event": "earnings", "label": "Earnings", "weight": 8.25, "count": 17}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 13, "negative_events": 5}, "market_context": {"has_market_context": true, "latest_close": 2.05, "latest_week": "2026-07-10", "one_week_move": -8.5, "four_week_move": 28.1, "twelve_week_move": 28.9, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.17633, "market_dynamics_buy_signal": false, "relative_strength": 33.943267, "fair_value_gap": 23.4, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 48.1511, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-8.5% over one week, +28.1% over four weeks, trend active, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 62, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 11}, {"label": "Stock Titan", "count": 10}, {"label": "Market source", "count": 9}, {"label": "TradingKey", "count": 6}, {"label": "GlobeNewswire", "count": 5}, {"label": "MSN", "count": 2}, {"label": "simplywall.st", "count": 2}, {"label": "MarketBeat", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 44}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 29}, {"label": "Earnings", "count": 17}, {"label": "Regulatory and legal", "count": 2}, {"label": "Analyst action", "count": 2}, {"label": "Capital return", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "80/100 classification confidence."}, {"label": "Company focus", "value": "44", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-8.5% over one week, +28.1% over four weeks, trend active, and near fair-value range."}, {"label": "Latest direct headline", "value": "Negative", "tone": "negative", "text": "IFRX - InflaRx NV Revenue Breakdown"}], "updated_at": "2026-07-16T07:05:18.302756+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}